ライフサイエンスコーパス: cytotoxic T-lymphocyte

1 nodes and cross-present antigen to activate cytotoxic T lymphocytes.

2 n of infected or transformed cells by CD8(+) cytotoxic T lymphocytes.

3 man pathogen that is kept in check by CD8(+) cytotoxic T lymphocytes.

4 more H-ras mutations and fewer DMBA-specific cytotoxic T lymphocytes.

5 or NFATc1 controls the cytotoxicity of mouse cytotoxic T lymphocytes.

6 substantial reduction in the number of tumor cytotoxic T lymphocytes.

7 d and antitumor immunity was mediated by CD8 cytotoxic T lymphocytes.

8 iminate minimal disease burden by generating cytotoxic T lymphocytes.

9 , and donor or more recently third-party EBV cytotoxic T lymphocytes.

10 of CD73, and thus increasing the activity of cytotoxic T lymphocytes.

11 n of distinct MHC class II-restricted CD4(+) cytotoxic T lymphocytes.

12 nding and presenting immunogenic peptides to cytotoxic T lymphocytes.

13 humans that is normally eliminated by CD8(+) cytotoxic T lymphocytes.

14 fected cells, thereby evading elimination by cytotoxic T-lymphocytes.

15 ws that NFATc1 binds many genes that control cytotoxic T lymphocyte activity.

16 he antigenic peptide repertoire presented to cytotoxic T lymphocytes and as a result can regulate cyt

17 Here, we engineer human beta-cell-specific cytotoxic T lymphocytes and demonstrate that T1-IFN augm

18 ) presents intracellular-derived peptides to cytotoxic T lymphocytes and its subcellular itinerary is

19 Cytotoxic T lymphocytes and natural killer cells express

20 protease found in the cytosolic granules of cytotoxic T lymphocytes and natural killer cells.

21 tivity we examined synapse formation between cytotoxic T lymphocytes and their targets.

22 tributed to the activation of tumor-reactive cytotoxic T lymphocytes and/or natural killer cells.

23 xperimental data of the dynamics and role of cytotoxic T lymphocytes, antibodies, and interferon and

24 f ipilimumab, a monoclonal antibody blocking cytotoxic T lymphocyte antigen (CTLA)-4, demonstrates th

25 Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed

26 , which include a receptor on T cells termed cytotoxic T lymphocyte antigen 4 (CTLA-4).

27 action with CD28 and its alternative ligand, cytotoxic T lymphocyte antigen 4 (CTLA-4).

28 death ligand-1 (PD-1/PD-L1), but not through cytotoxic T lymphocyte antigen 4 (CTLA4), was shown to b

29 kers for differentiation (CD127) and anergy (cytotoxic T lymphocyte antigen 4 [CTLA-4] and programmed

30 e been developed include ipilimumab, an anti-cytotoxic T lymphocyte antigen 4 antibody that enhances

31 Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with

32 Mice lacking the co-inhibitory receptor cytotoxic T lymphocyte antigen-4 (CTLA-4) develop fatal

33 ers of regulatory T cells (Tregs), increased cytotoxic T lymphocyte antigen-4 (CTLA-4) expression, an

34 Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a regulator

35 Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essentia

36 The protein cytotoxic T lymphocyte antigen-4 (CTLA-4) is an essentia

37 Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an inhibito

38 We evaluated Eomes and coinhibitory cytotoxic T lymphocyte antigen-4 (CTLA4) expression by a

39 New immune checkpoint inhibitors blocking cytotoxic T lymphocyte antigen-4 (CTLA4) or programmed d

40 provement in response to abatacept, a CTLA4 (cytotoxic T lymphocyte antigen-4)-immunoglobulin fusion

41 bitory signals in secondary lymphoid organs, cytotoxic T-lymphocyte antigen (CTLA)-4 antibodies media

42 nt of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed

43 ssion of programmed death 1 (PD-1) and lower cytotoxic T-lymphocyte antigen 4 (CTLA-4) expression tha

44 umab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4).

45 The dNP2-conjugated cytoplasmic domain of cytotoxic T-lymphocyte antigen 4 (dNP2-ctCTLA-4) negativ

46 pression (programmed cell death 1 [PD-1] and cytotoxic T-lymphocyte antigen 4 [CTLA-4]) was similar t

47 defensin, beta 4A [DEFB4A]) or dermal (IL22, cytotoxic T-lymphocyte antigen 4 [CTLA4], and CCR7) and

48 Neutralization of cytotoxic T-lymphocyte antigen 4 and transforming growth

49 a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour i

50 checkpoints (eg, programmed cell death 1 and cytotoxic T-lymphocyte antigen 4), are under investigati

51 T-cell responses, blocking antibodies (anti-cytotoxic T-lymphocyte antigen 4, anti-programmed death

52 a human monoclonal antibody targeted against cytotoxic T-lymphocyte antigen 4, has shown promise in t

53 of metastatic urothelial carcinoma, tubulin, cytotoxic T-lymphocyte antigen 4, Hsp27, and p53 are nov

54 and overexpression of regulatory molecules (cytotoxic T-lymphocyte antigen 4, programmed cell death

55 s combined with suboptimal concentrations of cytotoxic T-lymphocyte antigen 4-Ig or cyclosporine.

56 ses antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4.

57 T, insulin like growth factor 1 receptor and cytotoxic T-lymphocyte antigen 4.

58 ed in a murine tumor xenograft model of anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) immunotherapy

59 ssion of the negative costimulatory molecule cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells mod

60 via monoclonal antibodies, such as the anti-cytotoxic T-lymphocyte antigen-4 antibody (ipilimumab),

61 bitor), alone or combined with ipilimumab (a cytotoxic T-lymphocyte antigen-4 checkpoint inhibitor),

62 nd 1 expression, BRAF status, and best prior cytotoxic T-lymphocyte antigen-4 therapy response, then

63 Cytotoxic T lymphocytes are effector CD8(+) T cells that

64 IFN-gamma-producing cytotoxic T lymphocytes are essential for host defense a

65 Cytotoxic T-lymphocyte assay showed that CD8+ T cells fr

66 ndividuals, immunosuppression is mediated by cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and

67 , such as programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4), dow

68 of immune checkpoint pathways, in particular cytotoxic T-lymphocyte associated protein 4 and programm

69 ckpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and

70 in the expression of the inhibitory molecule cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) on

71 ocking inhibitory immune checkpoints such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) or

72 atment with monoclonal antibody specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an

73 A to an aptamer (apt) that selectively binds cytotoxic T lymphocyte-associated antigen 4 (CTLA4(apt))

74 ponsive beige-like anchor protein (LRBA) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) defi

75 nuclear factor kappaB-inducing kinase (NIK), cytotoxic T lymphocyte-associated antigen 4 (CTLA4), B-c

76 w costimulatory blockade agents, such as the cytotoxic T lymphocyte-associated antigen 4-Ig molecule

77 markers, including FOXP3, CD25, Helios, and cytotoxic T lymphocyte-associated antigen 4; and impaire

78 Monoclonal antibodies directed against cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), su

79 Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4; CD1

80 h in vitro blockade of programmed death-1 or cytotoxic T lymphocyte-associated antigen-4 increased T-

81 atory markers FOXP3, programmed death-1, and cytotoxic T lymphocyte-associated antigen-4 was examined

82 In phase I/II trials, the cytotoxic T lymphocyte-associated antigen-4-blocking mon

83 T-cell expression of programmed death-1 and cytotoxic T lymphocyte-associated antigen-4.

84 las (TCGA) demonstrate reduced expression of cytotoxic T lymphocyte-associated genes and IFN-gamma-in

85 kpoint blockade with antibodies specific for cytotoxic T lymphocyte-associated protein (CTLA)-4 or pr

86 une checkpoint inhibitory antibodies against cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and

87 1/programmed death ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) res

88 3 and immunosuppressive molecules, IL-10 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4).

89 ath protein (PD) 1-PD ligand 1/2 pathway and cytotoxic T lymphocyte-associated protein 4 are currentl

90 ng fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hi

91 ical trials investigating the combination of cytotoxic T lymphocyte-associated protein 4 inhibitors a

92 anti-programmed cell death protein 1 or anti-cytotoxic T lymphocyte-associated protein 4 is currently

93 ojix), a fusion protein that interferes with cytotoxic T lymphocyte-associated protein 4.

94 have been reported, favored by the fact that cytotoxic T lymphocyte-associated protein pathway has an

95 tance: Checkpoint blockade therapy targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and

96 Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blo

97 D-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] che

98 geted (BRAF or MEK) or an immune checkpoint (cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] or

99 th melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) pr

100 tic virus) in combination with ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 checkpoint i

101 Abatacept (cytotoxic T-lymphocyte-associated antigen 4-immunoglobul

102 anti-programmed cell death-1 (PD-1) or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) ant

103 Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is

104 pilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) sig

105 s that promote the function of T cells: anti-cytotoxic T-lymphocyte-associated protein 4 (alpha-CTLA-

106 activity, which resulted in up-regulation of cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) and

107 ed/refractory acute lymphocytic leukemia and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and

108 The mechanism of action of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) rem

109 IM-3), lymphocyte activation gene-3 (LAG-3), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), cl

110 treated with monoclonal antibodies blocking cytotoxic T-lymphocyte-associated protein 4 (CTLA-4; an

111 Cytotoxic T-lymphocyte-associated protein 4 (CTLA4), whi

112 r 2 (TLR2), which regulates the induction of cytotoxic T-lymphocyte-associated protein 4 (CTLA4).

113 Belatacept (cytotoxic T-lymphocyte-associated protein 4 Ig) is an em

114 G1 monoclonal antibody directed against the cytotoxic T-lymphocyte-associated protein 4 receptor tha

115 checkpoint blockade established by targeting cytotoxic T-lymphocyte-associated protein 4 with ipilimu

116 e that dual aOX40 (anti-CD134)/aCTLA-4 (anti-cytotoxic T-lymphocyte-associated protein 4) immunothera

117 alpha, interleukin-2, interleukin-7, CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), T-cell rec

118 tion of the autophagic machinery in DCs in a cytotoxic T-lymphocyte-associated protein 4-dependent (C

119 potential treatment, with administration of cytotoxic T-lymphocyte-associated protein 4-Ig reducing

120 These data suggest that cytotoxic T-lymphocyte-associated protein 4-Ig should be

121 NE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) mon

122 checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-associated protein 4 (CTLA4) or p

123 checkpoint blocking (ICB) antibodies against cytotoxic-T-lymphocyte-associated protein 4 or programme

124 ration programs through inhibitory receptor, cytotoxic-T-lymphocyte-associated protein-4 (CTLA-4).

125 window to impede protective immunity through cytotoxic-T-lymphocyte-associated protein-4 (CTLA-4).

126 ia have shown that the regulatory molecules, cytotoxic T-lymphocyte attenuator-4 (CTLA-4), lymphocyte

127 omplex (MHC) class I molecule HLA-A2 produce cytotoxic T lymphocytes bearing T cell receptors (TCRs)

128 sing the MHC class I molecule HLA-A2 produce cytotoxic T lymphocytes bearing T-cell receptors (TCRs)

129 Human CD8(+) cytotoxic T lymphocytes can mediate tumor regression in

130 y activated CD4(+) T-helper cells and CD8(+) cytotoxic T lymphocyte cells.

131 eradication is accomplishable by recruiting cytotoxic T lymphocytes, concomitant with downregulation

132 CMV replication in the same organs where CD4 cytotoxic T lymphocyte (CTL) activity was observed.

133 nced antigen-specific cross-presentation and cytotoxic T lymphocyte (CTL) activity.

134 The immunological synapse formed between a cytotoxic T lymphocyte (CTL) and an infected or transfor

135 immunodeficiencies characterized by impaired cytotoxic T lymphocyte (CTL) and natural killer (NK) cel

136 ause depletion of Tregs restored humoral and cytotoxic T lymphocyte (CTL) antiviral responses.

137 The rate at which a cytotoxic T lymphocyte (CTL) can survey for infected cel

138 Although cytotoxic T lymphocyte (CTL) control of HLH development

139 e transcription factor T-bet is critical for cytotoxic T lymphocyte (CTL) differentiation, but it is

140 Identification of CD8(+) cytotoxic T lymphocyte (CTL) epitopes has traditionally

141 thogenicity and disease outcome by targeting cytotoxic T lymphocyte (CTL) epitopes in Nef.

142 ing in-house bioinformatics pipelines, since cytotoxic T lymphocyte (CTL) escape can occur at differe

143 to downregulate MHC-I molecules and enhance cytotoxic T lymphocyte (CTL) evasion in human immunodefi

144 ates to evade host recognition and that CD8+ cytotoxic T lymphocyte (CTL) failure is due to the inabi

145 n causes the deterioration of virus-specific cytotoxic T lymphocyte (CTL) function and survival.

146 Cytotoxic T lymphocyte (CTL) function as assessed by inf

147 The centrosome is essential for cytotoxic T lymphocyte (CTL) function, contacting the pl

148 -1 expression, resulting in increased CD8(+) cytotoxic T lymphocyte (CTL) function.

149 t represents an important induction site for cytotoxic T lymphocyte (CTL) immunity to airborne pathog

150 ls should induce DSA synthesis but not naive cytotoxic T lymphocyte (CTL) precursors' priming via dir

151 id transcriptional changes that occur during cytotoxic T lymphocyte (CTL) proliferation and different

152 high-resolution mass spectrometry to map the cytotoxic T lymphocyte (CTL) proteome and the effect of

153 ortantly, rapamycin treatment did not impair cytotoxic T lymphocyte (CTL) recognition and killing of

154 assess how the naive epitope-specific CD8(+) cytotoxic T lymphocyte (CTL) repertoire translates to th

155 An effective cytotoxic T lymphocyte (CTL) response against intracellu

156 The CD8+ cytotoxic T lymphocyte (CTL) response is an important de

157 s are observed in the impact of the dominant cytotoxic T lymphocyte (CTL) response restricted by HLA-

158 als have indicated that AAV capsids induce a cytotoxic T lymphocyte (CTL) response that eliminates tr

159 g tumour-specific adaptive immunity, such as cytotoxic T lymphocyte (CTL) response, can result in pro

160 s have an activator function that triggers a cytotoxic T lymphocyte (CTL) response.

161 Cytotoxic T lymphocyte (CTL) responses against the HIV G

162 (iMC), which suppress specific and unrelated cytotoxic T lymphocyte (CTL) responses and are termed my

163 Therefore, Vif-specific cytotoxic T lymphocyte (CTL) responses and drugs that ma

164 , DTA-1-induced IL-9 promoted tumor-specific cytotoxic T lymphocyte (CTL) responses by enhancing the

165 HIV-specific cytotoxic T lymphocyte (CTL) responses decline following

166 ous studies have demonstrated that effective cytotoxic T lymphocyte (CTL) responses drive the selecti

167 ighlighted the ability of HIV to escape from cytotoxic T lymphocyte (CTL) responses that concurrently

168 fective priming of helper T cells but not of cytotoxic T lymphocyte (CTL) responses.

169 mmunity by adoptive transfer of EBV-specific cytotoxic T lymphocyte (CTL) therapy while highly effect

170 dust mite (HDM) challenge without affecting cytotoxic T lymphocyte (CTL), Th1 cell, or Th17 cell res

171 Anti-human immunodeficiency virus (HIV) cytotoxic T lymphocyte (CTL)-associated epitopes, evolut

172 malarial subunit vaccine inducing protective cytotoxic T lymphocyte (CTL)-mediated immunity could pav

173 Cytotoxic T lymphocyte (CTL)-mediated killing involves t

174 ther syntaxin 11 (Stx11) or Munc18-2 abolish cytotoxic T lymphocytes (CTL) and natural killer cell (N

175 Cytotoxic T lymphocytes (CTL) are a major factor in the

176 HIV-specific cytotoxic T lymphocytes (CTL) are preferentially primed

177 donor-derived cytomegalovirus (CMV) specific cytotoxic T lymphocytes (CTL) as immune reconstitution p

178 Cytotoxic T lymphocytes (CTL) from KO mice failed to mob

179 TERT-specific cytotoxic T lymphocytes (CTL) have been detected in the

180 xamined molecules associated with anergy and cytotoxic T lymphocytes (CTL) in peripheral blood mononu

181 ptively transferred ovalbumin (OVA)-specific cytotoxic T lymphocytes (CTL) induce lung injury in mice

182 of HIV.IMPORTANCE In HIV infection, although cytotoxic T lymphocytes (CTL) play a potentially critica

183 eless be efficiently cleared by infiltrating cytotoxic T lymphocytes (CTL) without compromising tumor

184 ukocytes in tumors, including tumor-specific cytotoxic T lymphocytes (CTL), is altered and results in

185 nvironment, IL-10 inhibits the activation of cytotoxic T lymphocytes (CTL), while IL-12 enhances CTL

186 ed immune responses, notably those of CD8(+) cytotoxic T lymphocytes (CTL).

187 ia contributes to tumoral immune escape from cytotoxic T lymphocytes (CTL).

188 al cell plasticity on targeted cell lysis by cytotoxic T lymphocytes (CTL).

189 assays were used to evaluate tumor-reactive cytotoxic T lymphocytes (CTL).

190 Viral factors (e.g. transmitted cytotoxic T- lymphocyte (CTL) escape mutations) or infan

191 HLA class I-restricted cytotoxic T-lymphocyte (CTL) escape mutations in HIV-1 t

192 mount a large, persistently activated CD8(+) cytotoxic T-lymphocyte (CTL) response against HTLV-I-inf

193 To induce a potent MHC I-restricted cytotoxic T-lymphocyte (CTL) response, cytosol delivery

194 To understand the interplay between host cytotoxic T-lymphocyte (CTL) responses and the mechanism

195 thodology for stimulating strong CD8alpha(+) cytotoxic T-lymphocyte (CTL) responses remains lacking.

196 In advanced age, decreased CD8(+) cytotoxic T-lymphocyte (CTL) responses to novel pathogen

197 Humoral, total T-cell, and CD8(+) cytotoxic T-lymphocyte (CTL) responses were studied befo

198 Cytotoxic-T lymphocyte (CTL) responses to epitopes in al

199 Cytotoxic-T-lymphocyte (CTL) escape mutations undermine

200 ciated with strong and potent HIV-1-specific cytotoxic-T-lymphocyte (CTL) responses restricted by pro

201 Here we show that CD8(+) T-cell (also called cytotoxic T lymphocytes, CTL) feedback activates the NLR

202 eral blood-derived, melanoma-reactive CD8(+) cytotoxic T lymphocytes (CTLs) alone is generally insuff

203 by presenting immunodominant HIV epitopes to cytotoxic T lymphocytes (CTLs) and CD4(+) T cells.

204 effects of adaptive and innate immune cells-cytotoxic T lymphocytes (CTLs) and natural killer (NK) c

205 Cytotoxic lymphocytes, encompassing cytotoxic T lymphocytes (CTLs) and natural killer (NK) c

206 8-2, facilitate cytolytic granule release by cytotoxic T lymphocytes (CTLs) and natural killer (NK) c

207 Cytotoxic T lymphocytes (CTLs) are highly effective seri

208 alysis of CD69 and CD25 levels revealed that cytotoxic T lymphocytes (CTLs) are partially activated i

209 Although CD8(+) cytotoxic T lymphocytes (CTLs) are protective in HIV-1 i

210 HCV-specific CD8(+) cytotoxic T lymphocytes (CTLs) are vital in the clearanc

211 Many pathogens evade cytotoxic T lymphocytes (CTLs) by downregulating HLA mol

212 Cytotoxic T lymphocytes (CTLs) constitute a major effect

213 These therapies are based on the idea that cytotoxic T lymphocytes (CTLs) directly recognize and re

214 Cytotoxic T lymphocytes (CTLs) eliminate infected and ne

215 CD8(+) cytotoxic T lymphocytes (CTLs) eliminate virally infecte

216 he tumors that express them, we expanded LMP-cytotoxic T lymphocytes (CTLs) from patients with lympho

217 CD8(+) cytotoxic T lymphocytes (CTLs) have potent antitumor act

218 apies that boost the anti-tumor responses of cytotoxic T lymphocytes (CTLs) have shown promise; howev

219 ls (FDCs), low frequencies of virus-specific cytotoxic T lymphocytes (CTLs) in B cell follicles, expa

220 e of influenza A virus (IAV)-specific CD8(+) cytotoxic T lymphocytes (CTLs) in heterosubtypic cross-p

221 tion and numerical reduction of HBV-specific cytotoxic T lymphocytes (CTLs) in the liver and peripher

222 Cytolytic activity by CD8(+) cytotoxic T lymphocytes (CTLs) is a powerful strategy fo

223 resently assumed that lethal hit delivery by cytotoxic T lymphocytes (CTLs) is mechanistically linked

224 ive cell transfer utilizing tumour-targeting cytotoxic T lymphocytes (CTLs) is one of the most effect

225 Cytotoxic T lymphocytes (CTLs) kill target cells by the

226 Cytotoxic T lymphocytes (CTLs) kill virus-infected cells

227 Failure of cytotoxic T lymphocytes (CTLs) or natural killer (NK) ce

228 Tumor-specific CD8(+) cytotoxic T lymphocytes (CTLs) play a critical role in a

229 Cytotoxic T lymphocytes (CTLs) play an important role in

230 tion of tumor antigen-specific (TA-specific) cytotoxic T lymphocytes (CTLs) present within tumors fro

231 o examine how cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTLs) respond to allogeneic ant

232 Adenovirus infection induced cytotoxic T lymphocytes (CTLs) targeted against the viru

233 Cytotoxic T lymphocytes (CTLs) use polarized secretion t

234 study the dynamics of virus replication and cytotoxic T lymphocytes (CTLs) within a metapopulation o

235 virus-specific immune mechanisms, including cytotoxic T lymphocytes (CTLs), can clear infected cells

236 The recall of memory CD8(+) cytotoxic T lymphocytes (CTLs), elicited by prior virus

237 of producing clinical-grade BCR-ABL-specific cytotoxic T lymphocytes (CTLs), endowed with antileukemi

238 including studies on tumor-infiltrating CD8+ cytotoxic T lymphocytes (CTLs), have led to new immunoth

239 on of AKT and mTOR are impaired in antiviral cytotoxic T lymphocytes (CTLs), resulting in enhanced ac

240 ions in both transferred OT-1 and endogenous cytotoxic T lymphocytes (CTLs).

241 d cells, latently infected cells, virus, and cytotoxic T lymphocytes (CTLs).

242 nd short-lived effector and memory precursor cytotoxic T lymphocytes (CTLs).

243 UL11 affects the function of virus-specific cytotoxic T lymphocytes (CTLs).

244 oviruses can be recognized by HIV-1-specific cytotoxic T lymphocytes (CTLs).

245 ion, differentiation, and function of CD8(+) cytotoxic T lymphocytes (CTLs).

246 uman leukocyte antigen (HLA)-B*18-restricted cytotoxic T lymphocytes (CTLs).

247 hare a pathomechanism with the activation of cytotoxic T lymphocytes (CTLs).

248 roperties is a key step in the generation of cytotoxic T lymphocytes (CTLs).

249 vironment that protects malignant cells from cytotoxic T lymphocytes (CTLs).

250 broad, highly functional cytotoxic T cells (cytotoxic T lymphocytes [CTLs]) against the HIV-1 Gag pr

251 els of let-7 expression, while generation of cytotoxic T lymphocytes depends upon T cell receptor-med

252 only in tristetraprolin-deficient mice after cytotoxic T lymphocyte depletion, but also in WSX-1/tris

253 Natural killer cells and cytotoxic T-lymphocytes deploy perforin and granzymes to

254 utologous, ex vivo expanded, virus-specific, cytotoxic T-lymphocytes derived from HIV-infected patien

255 ate that NFATc1 is an important regulator of cytotoxic T lymphocyte effector functions.NFAT nuclear t

256 et al. (2016) showed that forces exerted by cytotoxic T lymphocytes enhance the function of the pore

257 ent soluble and cell-associated tumor Ags to cytotoxic T lymphocytes equally well as BDCA3(+) mDCs.

258 nt reservoir also contains a large number of cytotoxic T lymphocyte escape mutants, presenting anothe

259 We addressed the ability of cytotoxic T lymphocytes from 30 untreated HIV-infected s

260 regulatory pathway for IL-27 expression and cytotoxic T lymphocyte function mediated by tristetrapro

261 ease in nonmodified CD4(+) T cells, enhanced cytotoxic T lymphocyte function, and antibody responses.

262 nts has been associated with efficient CD8(+)cytotoxic T-lymphocyte function.

263 n (HLA) class I molecules for more efficient cytotoxic T lymphocyte generation.

264 Passive transfer of virus-specific cytotoxic T lymphocytes has been used in humans and may

265 to prevent EC death induced by TNF-alpha and cytotoxic T lymphocytes in vitro.

266 ction of regulatory T cells able to suppress cytotoxic T lymphocyte induction in MLCs, and for the ab

267 on, and adjunct therapy such as CMV-specific cytotoxic T-lymphocyte infusions.

268 ization' was reported at the contact area of cytotoxic T lymphocytes interacting with target cells.

269 ed the growth of liver metastases, driven by cytotoxic T-lymphocyte-mediated antitumor immunity.

270 attenuates liver carcinogenesis and induces cytotoxic T-lymphocyte-mediated regression of establishe

271 der characterized by unbridled activation of cytotoxic T lymphocytes, natural killer (NK) cells, and

272 mour regression that is dependent on neither cytotoxic T lymphocytes nor humoral immune response.

273 lin double knockout) leads to a reduction in cytotoxic T lymphocyte numbers.

274 es differentiate into either CD8alphabeta(+) cytotoxic T lymphocytes or CD4(+) helper T cells.

275 n the intrinsic characteristics of the naive cytotoxic T lymphocyte precursor pool and extrinsic (lik

276 as vaccines in these mice were deficient in cytotoxic T lymphocytes priming and IL-12 induction in c

277 Cytotoxic T lymphocytes recognize non-self peptides and

278 udovirion (PsV)-based assays, and a vigorous cytotoxic T lymphocyte response by enzyme-linked immunos

279 eness of CD8Treg cells, the magnitude of the cytotoxic T lymphocyte response can be increased.

280 of elimination of these cells by either the cytotoxic T lymphocyte response or other immune cell sub

281 outgrowing EBV-infected B cells and the EBV cytotoxic T lymphocyte response, and targeting infected

282 ndritic cell is critical for the size of the cytotoxic T lymphocyte response, because dendritic cells

283 T lymphocytes, suggesting a robust adaptive cytotoxic T-lymphocyte response may, in part, confer res

284 apes the tumour microenvironment and induces cytotoxic T lymphocyte responses against an independent

285 was correlated with increased likelihood of cytotoxic T lymphocyte responses and frequency of viral

286 he HLA alleles C*03:03/C*03:04 no allogeneic cytotoxic T-lymphocyte responses are detected in vitro.

287 nnate effector natural killer (NK) cells and cytotoxic T-lymphocyte responses to leukemia-associated

288 human activated autoreactive CD8(+) T-cell (cytotoxic T lymphocyte) responses within the islets of p

289 Cytotoxic T lymphocytes select for virus escape mutants

290 Activation of Nfatc1 (-/-) cytotoxic T lymphocytes showed a defective cytoskeleton

291 d T-cell intracytoplasmic antigen 1-positive cytotoxic T lymphocytes, suggesting a robust adaptive cy

292 deplete B cells or adoptive transfer of EBV cytotoxic T lymphocyte to reconstitute immunity.

293 ed potent bispecific antibodies that recruit cytotoxic T lymphocytes to Her2 and CD20 positive cancer

294 entiation of naive CD8 T cells into effector cytotoxic T lymphocytes upon antigen stimulation is nece

295 Antigen presentation to cytotoxic T lymphocytes via major histocompatibility com

296 stantially reduce the risk of destruction by cytotoxic T lymphocytes, whereas use of alternative sero

297 ticulum, herpes simplex virus is hidden from cytotoxic T lymphocytes, which may contribute to establi

298 surfaces is a key step in the activation of cytotoxic T lymphocytes, which mediate the killing of pa

299 frequent peripheral antigen-specific CD8(+) cytotoxic T lymphocytes with immune memory than IFA-emul

300 While the emergence of WT1-specific cytotoxic T lymphocytes (WT1-CTL) has been correlated wi